The nation of Zimbabwe has turned down a substantial American health deal valued at $367m (272 million pounds) over five years because of the United States' request for confidential biological samples.
This rejection was revealed after a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson has since stated that the United States was requesting health data for research and commercial purposes while was not willing to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for continued dialogue to reach a agreement suitable to all parties so the nation's vital HIV programme can continue.
Broader Background
This development comes after a similar case in neighbouring Kenya, where a high court suspended a related deal with the US following concerns were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was seeking government-to-government deals to boost transparency and accountability.
Based on statements, Sixteen African countries have so far signed these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded significant benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, without any equivalent promise of benefiting from any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"In essence, our country would provide the raw materials for medical research with no certainty that the resulting innovations would be accessible to our people if a new disease outbreak emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining structures previously established through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This framework is intended to ensure that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage further discussions with our US partners on how subsequent collaboration might be arranged in a manner that respects the independence and dignity of both nations."
Health Experts Reaction
A leading public health body said it understood the government's concerns, but recommended that talks should continue given that a large portion of the country's HIV programmes relied on international support.
"In cases where technical issues arise, including those involving information security or implementation frameworks, these can frequently be addressed via detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the complex tensions between receiving much-needed foreign assistance and protecting local interests in an ever more data-driven world.